Use a pass/hold gate. A cheap quote should not offset an unresolved product, licensing or quality issue.
| Gate | Evidence to request | Recommended hold trigger |
|---|---|---|
| Identity and supply chain | Contracting entity, dispensing or manufacturing location, seller, shipper and product identifiers | Unexplained entity mismatch or undisclosed fulfilment facility |
| Route eligibility | Intended use, relevant permissions and preparation-specific assessment where compounding is proposed | Reliance only on a licence, prescription, registration or historic shortage |
| Product and quality | Provenance, applicable inspection records, quality responses, storage instructions and recall procedures | Unresolved identity, sterility, potency, handling or investigation concerns |
| Destination readiness | State-specific permissions and written product acceptance | A national marketing statement without facility-level evidence |
| Clinical responsibility | Prescribing, counselling, complaint and adverse-event responsibilities | Commercial staff determining clinical changes or unclear escalation ownership |
| Information governance | Data-flow map, role assessment, security evidence and appropriate agreements | Unknown data recipients, unclear permitted uses or unreviewed subcontractors |
What do registration and inspection records actually establish?
Use public records as evidence inputs, not approval badges. FDA's outsourcing register contains registration and inspection-related information, and some fields are supplier-reported rather than FDA-verified. FDA also explains that a Form 483 records inspection observations and is not a final agency determination of a violation. Review the observation, response, subsequent action and current status together. (fda.gov)
For wholesalers, FDA says appropriate licensing and annual reporting are required for authorised-trading-partner status. Appearance in its reporting database does not itself establish FDA approval or compliance with all applicable requirements. (fda.gov)
How should a multi-state pharmacy coverage matrix work?
Use one row per dispensing facility, destination state and relevant activity—not one row per brand.
Suggested columns are legal entity, facility address, home-state licence, destination permission, sterile-compounding or outsourcing permission where relevant, restrictions, expiry, disciplinary review, exact product acceptance, operational capacity and evidence date.
California illustrates why the distinctions matter: a nonresident pharmacy shipping prescription medicines to its residents needs both a valid home-state licence and a California nonresident licence. Nonresident sterile compounding has an additional licensing requirement. These examples are not a substitute for reviewing every target state. (pharmacy.ca.gov)
How should clinics compare cold-chain and vial-wastage claims?
Require presentation-specific handling evidence and an executable exception process. FDA has reported concerns about compounded injectable GLP-1 products arriving warm or inadequately refrigerated. Its current advice also addresses contamination risk and discarding compounded multi-dose vials within 28 days of first use, even where a compounder's instructions allow longer. (fda.gov)
Ask the supplier to distinguish unopened shelf life, post-opening limits and shipping-excursion assessment. Do not model every labelled milligram as usable inventory, and do not apply a compounded-vial instruction indiscriminately to every approved presentation.
Is a business associate agreement always the answer?
No; determine the parties' actual roles and data uses. HHS distinguishes treatment disclosures to another healthcare provider from arrangements in which a business associate performs functions on a covered entity's behalf. Technology, analytics and other service relationships therefore require role-specific assessment rather than a blanket assumption that every pharmacy handoff has the same contracting requirement. (hhs.gov)
Explore the table row by row
A working view of the research
Identity and supply chain
- Evidence to request
- Contracting entity, dispensing or manufacturing location, seller, shipper and product identifiers
- Recommended hold trigger
- Unexplained entity mismatch or undisclosed fulfilment facility
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
- pharmacy.ca.gov · Source 3 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
- fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- hhs.gov · Source 5 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html